Is it safe to initiate combination therapy with paroxetine (Paxil) and bupropion (Wellbutrin), and what dosing and monitoring are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Combination Therapy with Paroxetine and Bupropion

Combining paroxetine (Paxil) and bupropion (Wellbutrin) is generally safe and can be initiated together, but requires careful attention to drug interactions, particularly bupropion's inhibition of CYP2D6 which significantly increases paroxetine levels.

Key Drug Interaction Considerations

Bupropion is a potent CYP2D6 inhibitor that can substantially increase plasma concentrations of paroxetine 1. This interaction is clinically significant because:

  • Paroxetine is metabolized primarily through CYP2D6
  • Bupropion inhibits this enzyme, potentially increasing paroxetine exposure
  • Similar interactions have been documented with other SSRIs metabolized by CYP2D6 2

Critical caveat: The combination of bupropion with paroxetine has been associated with severe bradycardia and atrioventricular block when used with beta-blockers like metoprolol, due to the compounded CYP2D6 inhibition 2, 3. Screen for concurrent cardiovascular medications before initiating.

Recommended Dosing Strategy

Starting Regimen

For treatment-naive patients or first-line therapy:

  • Paroxetine: Start at 10 mg daily (morning or evening) 4, 5
  • Bupropion: Start at 150 mg once daily in the morning 4, 1
  • Increase bupropion to 150 mg twice daily after 3 days if tolerated 4
  • Maximum bupropion dose: 300 mg/day (150 mg twice daily) 4, 1

For augmentation in partial responders:

  • If patient is already on paroxetine monotherapy, add bupropion SR 150 mg/day initially
  • Monitor closely for 1-2 weeks before increasing bupropion dose
  • Consider that paroxetine levels may increase by 2-3 fold due to CYP2D6 inhibition 2
  • May need to reduce paroxetine dose if side effects emerge after adding bupropion

Dose Titration

  • Increase paroxetine by 10 mg increments every 5-7 days as tolerated 4
  • Maximum paroxetine: 40 mg/day (standard); 50 mg/day (elderly/debilitated) 4, 5
  • Bupropion second dose should be given before 3 PM to minimize insomnia 4

Clinical Evidence for Combination

The combination has demonstrated efficacy in two key scenarios:

1. Treatment-resistant depression: Open-label studies show 70-78% of partial responders to SSRI monotherapy improved with bupropion augmentation 6, 7, 8. One controlled trial found combination therapy from treatment initiation achieved faster remission (week 2: 18% vs 0% for monotherapies) 9.

2. SSRI-induced sexual dysfunction: Bupropion augmentation significantly improved sexual dysfunction, particularly orgasmic delay, in 78% of patients 6, 8.

Monitoring Requirements

Initial Assessment (Before Starting)

  • Screen for seizure risk factors (stroke, brain metastases, eating disorders) - absolute contraindication to bupropion 10, 1
  • Screen for bipolar disorder risk (detailed psychiatric and family history) 5
  • Document concurrent medications, especially:
    • Beta-blockers (metoprolol, propranolol)
    • MAO inhibitors (14-day washout required) 5, 1
    • Other CYP2D6 substrates (antipsychotics, Type 1C antiarrhythmics) 1

Ongoing Monitoring

  • First 2 weeks: Monitor for serotonin syndrome symptoms (agitation, confusion, tremor, tachycardia, hyperthermia) 11, 5
  • Weeks 2-4: Assess for emerging suicidality, agitation, or mood destabilization 5
  • Week 4-8: Evaluate therapeutic response; full trial requires 4-8 weeks 4
  • Monitor for common side effects:
    • Paroxetine: GI symptoms, sexual dysfunction, sedation 4
    • Bupropion: Insomnia, dry mouth, activation 4

Contraindications and Special Populations

Absolute contraindications:

  • Concurrent MAOI use (14-day washout required) 5, 1
  • Seizure disorder or conditions increasing seizure risk 10, 1
  • Eating disorders (for bupropion) 10
  • Concurrent thioridazine use (for paroxetine) 5

Elderly/debilitated patients:

  • Start paroxetine at 12.5 mg/day (if using CR formulation) or 10 mg/day (immediate release) 5
  • Use lower bupropion doses (37.5 mg initially, titrate slowly) 4
  • Maximum paroxetine: 40 mg/day in elderly 5

Pregnancy considerations:

  • Paroxetine has 2-3 fold increased risk of cardiac malformations (particularly VSDs) in first trimester 5
  • Consider tapering paroxetine in third trimester due to neonatal complications 5
  • Weigh risks vs benefits carefully; consider alternative SSRIs if pregnancy planned

Discontinuation Protocol

Never stop abruptly - both medications require gradual taper:

  • Paroxetine: Taper over 10-14 days minimum to avoid discontinuation syndrome (dizziness, paresthesias, anxiety, GI symptoms) 4, 11, 5
  • Bupropion: Can be discontinued more rapidly but gradual reduction preferred
  • If discontinuing both, taper paroxetine first (higher discontinuation syndrome risk)
  • Resume previous dose if intolerable symptoms emerge, then taper more gradually 5

Common Pitfalls to Avoid

  1. Starting both at full doses simultaneously - increases side effect burden and makes it difficult to identify which medication is causing problems
  2. Ignoring cardiovascular medication interactions - particularly dangerous with beta-blockers 2, 3
  3. Inadequate seizure risk screening - bupropion is absolutely contraindicated with seizure history 10
  4. Failing to warn about insomnia - give second bupropion dose before 3 PM 4
  5. Not monitoring for bipolar conversion - antidepressant combinations may precipitate mania in undiagnosed bipolar disorder 5

References

Research

[Interactions between metoprolol and antidepressants].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2011

Guideline

smoking cessation, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.